Cargando…

An appraisal of allergic disorders in India and an urgent call for action

India is the second most populous country in the world with a population of nearly 1.3 billion, comprising 20% of the global population. There are an estimated 37.5 million cases of asthma in India, and recent studies have reported a rise in prevalence of allergic rhinitis and asthma. Overall, 40–50...

Descripción completa

Detalles Bibliográficos
Autores principales: Krishna, Mamidipudi Thirumala, Mahesh, Padukudru Anand, Vedanthan, Pudupakkam, Moitra, Saibal, Mehta, Vinay, Christopher, Devasahayam Jesudas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398972/
https://www.ncbi.nlm.nih.gov/pubmed/32774662
http://dx.doi.org/10.1016/j.waojou.2020.100446
_version_ 1783566054267551744
author Krishna, Mamidipudi Thirumala
Mahesh, Padukudru Anand
Vedanthan, Pudupakkam
Moitra, Saibal
Mehta, Vinay
Christopher, Devasahayam Jesudas
author_facet Krishna, Mamidipudi Thirumala
Mahesh, Padukudru Anand
Vedanthan, Pudupakkam
Moitra, Saibal
Mehta, Vinay
Christopher, Devasahayam Jesudas
author_sort Krishna, Mamidipudi Thirumala
collection PubMed
description India is the second most populous country in the world with a population of nearly 1.3 billion, comprising 20% of the global population. There are an estimated 37.5 million cases of asthma in India, and recent studies have reported a rise in prevalence of allergic rhinitis and asthma. Overall, 40–50% of paediatric asthma cases in India are uncontrolled or severe. Treatment of allergic rhinitis and asthma is sub-optimal in a significant proportion of cases due to multiple factors relating to unaffordability to buy medications, low national gross domestic product, religious beliefs, myths and stigma regarding chronic ailment, illiteracy, lack of allergy specialists, and lack of access to allergen-specific immunotherapy for allergic rhinitis and biologics for severe asthma. High quality allergen extracts for skin tests and adrenaline auto-injectors are currently not available in India. Higher postgraduate specialist training programmes in Allergy and Immunology are also not available. Another major challenge for the vast majority of the Indian population is an unacceptably high level of exposure to particulate matter (PM)(2.5) generated from traffic pollution and use of fossil fuel and biomass fuel and burning of incense sticks and mosquito coils. This review provides an overview of the burden of allergic disorders in India. It appraises current evidence and justifies an urgent need for a strategic multipronged approach to enhance quality of care for allergic disorders. This may include creating an infrastructure for education and training of healthcare professionals and patients and involving regulatory authorities for making essential treatments accessible at subsidised prices. It calls for research into better phenotypic characterisation of allergic disorders, as evidence generated from high income western countries are not directly applicable to India, due to important confounders such as ethnicity, air pollution, high rates of parasitic infestation, and other infections.
format Online
Article
Text
id pubmed-7398972
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher World Allergy Organization
record_format MEDLINE/PubMed
spelling pubmed-73989722020-08-06 An appraisal of allergic disorders in India and an urgent call for action Krishna, Mamidipudi Thirumala Mahesh, Padukudru Anand Vedanthan, Pudupakkam Moitra, Saibal Mehta, Vinay Christopher, Devasahayam Jesudas World Allergy Organ J Article India is the second most populous country in the world with a population of nearly 1.3 billion, comprising 20% of the global population. There are an estimated 37.5 million cases of asthma in India, and recent studies have reported a rise in prevalence of allergic rhinitis and asthma. Overall, 40–50% of paediatric asthma cases in India are uncontrolled or severe. Treatment of allergic rhinitis and asthma is sub-optimal in a significant proportion of cases due to multiple factors relating to unaffordability to buy medications, low national gross domestic product, religious beliefs, myths and stigma regarding chronic ailment, illiteracy, lack of allergy specialists, and lack of access to allergen-specific immunotherapy for allergic rhinitis and biologics for severe asthma. High quality allergen extracts for skin tests and adrenaline auto-injectors are currently not available in India. Higher postgraduate specialist training programmes in Allergy and Immunology are also not available. Another major challenge for the vast majority of the Indian population is an unacceptably high level of exposure to particulate matter (PM)(2.5) generated from traffic pollution and use of fossil fuel and biomass fuel and burning of incense sticks and mosquito coils. This review provides an overview of the burden of allergic disorders in India. It appraises current evidence and justifies an urgent need for a strategic multipronged approach to enhance quality of care for allergic disorders. This may include creating an infrastructure for education and training of healthcare professionals and patients and involving regulatory authorities for making essential treatments accessible at subsidised prices. It calls for research into better phenotypic characterisation of allergic disorders, as evidence generated from high income western countries are not directly applicable to India, due to important confounders such as ethnicity, air pollution, high rates of parasitic infestation, and other infections. World Allergy Organization 2020-08-01 /pmc/articles/PMC7398972/ /pubmed/32774662 http://dx.doi.org/10.1016/j.waojou.2020.100446 Text en © 2020 Published by Elsevier Inc. on behalf of World Allergy Organization. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Krishna, Mamidipudi Thirumala
Mahesh, Padukudru Anand
Vedanthan, Pudupakkam
Moitra, Saibal
Mehta, Vinay
Christopher, Devasahayam Jesudas
An appraisal of allergic disorders in India and an urgent call for action
title An appraisal of allergic disorders in India and an urgent call for action
title_full An appraisal of allergic disorders in India and an urgent call for action
title_fullStr An appraisal of allergic disorders in India and an urgent call for action
title_full_unstemmed An appraisal of allergic disorders in India and an urgent call for action
title_short An appraisal of allergic disorders in India and an urgent call for action
title_sort appraisal of allergic disorders in india and an urgent call for action
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398972/
https://www.ncbi.nlm.nih.gov/pubmed/32774662
http://dx.doi.org/10.1016/j.waojou.2020.100446
work_keys_str_mv AT krishnamamidipudithirumala anappraisalofallergicdisordersinindiaandanurgentcallforaction
AT maheshpadukudruanand anappraisalofallergicdisordersinindiaandanurgentcallforaction
AT vedanthanpudupakkam anappraisalofallergicdisordersinindiaandanurgentcallforaction
AT moitrasaibal anappraisalofallergicdisordersinindiaandanurgentcallforaction
AT mehtavinay anappraisalofallergicdisordersinindiaandanurgentcallforaction
AT christopherdevasahayamjesudas anappraisalofallergicdisordersinindiaandanurgentcallforaction
AT krishnamamidipudithirumala appraisalofallergicdisordersinindiaandanurgentcallforaction
AT maheshpadukudruanand appraisalofallergicdisordersinindiaandanurgentcallforaction
AT vedanthanpudupakkam appraisalofallergicdisordersinindiaandanurgentcallforaction
AT moitrasaibal appraisalofallergicdisordersinindiaandanurgentcallforaction
AT mehtavinay appraisalofallergicdisordersinindiaandanurgentcallforaction
AT christopherdevasahayamjesudas appraisalofallergicdisordersinindiaandanurgentcallforaction